Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

The pharma giant said its oral GLP-1 drug demonstrated significant efficacy results and a safety profile consistent with its ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

Shares of Eli Lilly LLY soared 14.3% on April 17 after data from a late ... T2D and Wegovy for weight management. NVO also markets Rybelsus as an oral medication for adults with T2D to control ...